Browse > Article
http://dx.doi.org/10.19125/jmrd.2021.5.1.8

Glutaric Aciduria Type I: Overview  

Kim, Su Jin (Department of Pediatrics, Inha University Hospital, Inha University College of Medicine)
Publication Information
Journal of mucopolysaccharidosis and rare diseases / v.5, no.1, 2021 , pp. 8-11 More about this Journal
Abstract
Glutaric aciduria type 1 (GA1; OMIM #231670) is a rare autosomal recessive-inherited neurometabolic disorder caused by the deficiency of glutaryl-CoA dehydrogenase (GCDH), which is encoded by the GCDH gene. It results in the accumulation of glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), glutaconic acid, and glutarylcarnitine (C5DC). These metabolites are considered to damage the striatum through an excitotoxic mechanism. The treatments of GA1 known to date are metabolic maintenance treatment based on a low-lysine diet and emergency treatment during acute illness. However, treatment after the onset of neurological symptoms has limited effectiveness and is associated with poor outcomes, and the effect of treatment and disease course after treatment are not good. After the implementation of newborn screening, the incidence of acute encephalopathic crisis fell to 10%-20% with early diagnosis, preventative dietary management, and aggressive medical intervention during acute episodes. Recently, several cohort studies have been published on the natural course and treatment of GA1 patients. This mini review will cover the clinical symptoms, natural history, and treatment of GA1 through a literature review.
Keywords
Glutaric aciduria type 1; Glutaryl-CoA dehydrogenase; Metabolic disease; Organic aciduria;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Boy N, Garbade SF, Heringer J, Seitz A, Kolker S, Harting I. Patterns, evolution, and severity of striatal injury in insidious- vs acute-onset glutaric aciduria type 1. J Inherit Metab Dis 2019;42:117-27.   DOI
2 Lund TM, Christensen E, Kristensen AS, Schousboe A, Lund AM. On the neurotoxicity of glutaric, 3-hydroxyglutaric, and trans-glutaconic acids in glutaric acidemia type 1. J Neurosci Res 2004;77:143-7.   DOI
3 Kurkina MV, Mihaylova SV, Baydakova GV, Saifullina EV, Korostelev SA, Pyankov DV, et al. Molecular and biochemical study of glutaric aciduria type 1 in 49 Russian families: nine novel mutations in the GCDH gene. Metab Brain Dis 2020;35:1009-16.   DOI
4 Pierson TM, Nezhad M, Tremblay MA, Lewis R, Wong D, Salamon N, et al. Adult-onset glutaric aciduria type I presenting with white matter abnormalities and subependymal nodules. Neurogenetics. 2015;16:325-8.   DOI
5 Strauss KA, Williams KB, Carson VJ, Poskitt L, Bowser LE, Young M, et al. Glutaric acidemia type 1: Treatment and outcome of 168 patients over three decades. Mol Genet Metab 2020;131:325-40.   DOI
6 Boy N, Muhlhausen C, Maier EM, Heringer J, Assmann B, Burgard P, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis 2017;40:75-101.   DOI
7 Bernstein L, Coughlin CR, Drumm M, Yannicelli S, Rohr F. Inconsistencies in the Nutrition Management of Glutaric Aciduria Type 1: An International Survey. Nutrients 2020;12.
8 Larson A, Goodman S. Glutaric Acidemia Type 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, et al., editors. GeneReviews((R)). Seattle (WA) 1993.
9 Zschocke J, Quak E, Guldberg P, Hoffmann GF. Mutation analysis in glutaric aciduria type I. J Med Genet 2000;37:177-81.   DOI
10 Gurbuz BB, Yilmaz DY, Coskun T, Tokatli A, Dursun A, Sivri HS. Glutaric aciduria type 1: Genetic and phenotypic spectrum in 53 patients. Eur J Med Genet 2020;63:104032.   DOI
11 Kolker S, Christensen E, Leonard JV, Greenberg CR, Boneh A, Burlina AB, et al. Diagnosis and management of glutaric aciduria type I-revised recommendations. J Inherit Metab Dis 2011;34:677-94.   DOI
12 Park JD, Lim B, Kim KJ, Hwang YS, Kim SK, Kang SH, et al. Glutaric aciduria type 1 in Korea: report of two novel mutations. J Korean Med Sci 2010;25:957-60.   DOI
13 Wang Q, Li X, Ding Y, Liu Y, Song J, Yang Y. Clinical and mutational spectra of 23 Chinese patients with glutaric aciduria type 1. Brain Dev 2014;36:813-22.   DOI
14 Merinero B, Perez-Cerda C, Font LM, Garcia MJ, Aparicio M, Lorenzo G, et al. Variable clinical and biochemical presentation of seven Spanish cases with glutaryl-CoA-dehydrogenase deficiency. Neuropediatrics 1995;26:238-42.   DOI
15 Song JY, Kim CM, Shin YL, Yoo HW. A case of glutaric aciduria type 1. J Korean Pediatr Soc 2002;45:1278-82.
16 Kim HS, Yu HJ, Lee J, Park HD, Kim JH, Shin HJ, et al. A Korean patient with glutaric aciduria type 1 with a novel mutation in the glutaryl CoA dehydrogenase gene. Ann Clin Lab Sci 2014;44:213-6.
17 Kolker S, Christensen E, Leonard JV, Greenberg CR, Burlina AB, Burlina AP, et al. Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). J Inherit Metab Dis 2007;30:5-22.   DOI
18 Viau K, Ernst SL, Vanzo RJ, Botto LD, Pasquali M, Longo N. Glutaric acidemia type 1: outcomes before and after expanded newborn screening. Mol Genet Metab 2012;106:430-8.   DOI
19 Boy N, Mengler K, Heringer-Seifert J, Hoffmann GF, Garbade SF, Kolker S. Impact of newborn screening and quality of therapy on the neurological outcome in glutaric aciduria type 1: a meta-analysis. Genet Med 2021;23:13-21.   DOI
20 Kulkens S, Harting I, Sauer S, Zschocke J, Hoffmann GF, Gruber S, et al. Late-onset neurologic disease in glutarylCoA dehydrogenase deficiency. Neurology 2005;64:2142-4.   DOI
21 Boy N, Mengler K, Thimm E, Schiergens KA, Marquardt T, Weinhold N, et al. Newborn screening: A disease-changing intervention for glutaric aciduria type 1. Ann Neurol 2018;83:970-9.   DOI
22 Martner EMC, Maier EM, Mengler K, Thimm E, Schiergens KA, Marquardt T, et al. Impact of interventional and noninterventional variables on anthropometric long-term development in glutaric aciduria type 1: A national prospective multi-centre study. J Inherit Metab Dis 2020.
23 Tsai FC, Lee HJ, Wang AG, Hsieh SC, Lu YH, Lee MC, et al. Experiences during newborn screening for glutaric aciduria type 1: Diagnosis, treatment, genotype, phenotype, and outcomes. J Chin Med Assoc 2017;80:253-61.   DOI
24 Sitta A, Guerreiro G, de Moura Coelho D, da Rocha VV, Dos Reis BG, Sousa C, et al. Clinical, biochemical and molecular findings of 24 Brazilian patients with glutaric acidemia type 1: 4 novel mutations in the GCDH gene. Metab Brain Dis 2021;36:205-12.   DOI
25 Mushimoto Y, Fukuda S, Hasegawa Y, Kobayashi H, Purevsuren J, Li H, et al. Clinical and molecular investigation of 19 Japanese cases of glutaric acidemia type 1. Mol Genet Metab 2011;102:343-8.   DOI
26 van der Watt G, Owen EP, Berman P, Meldau S, Watermeyer N, Olpin SE, et al. Glutaric aciduria type 1 in South Africa-high incidence of glutaryl-CoA dehydrogenase deficiency in black South Africans. Mol Genet Metab 2010;101:178-82.   DOI
27 Mhanni A, Aylward N, Boy N, Martin B, Sharma A, Rock-man-Greenberg C. Outcome of the glutaric aciduria type 1 (GA1) newborn screening program in Manitoba: 1980-2020. Mol Genet Metab Rep 2020;25:100666.   DOI